Thermo Fisher Scientific to Acquire Solventum’s Purification and Filtration Business

Solventum’s Purification & Filtration business is recognized as a leading provider in its field, operating globally with a workforce of approximately 2,500 employees. In 2024, the segment generated an impressive revenue of about $1 billion. The acquisition aligns seamlessly with Thermo Fisher's existing bioproduction business, which already boasts a strong portfolio of cell culture media and single-use technologies.

Marc N. Casper, chairman, president, and CEO of Thermo Fisher, emphasized the strategic fit of the acquisition, stating, “The addition of Solventum’s business is an outstanding strategic fit with our company and will create significant value for our customers and shareholders.” He further noted that Solventum’s solutions would enhance Thermo Fisher’s bioprocessing portfolio, catering to a rapidly growing market.

The transaction is expected to close by the end of 2025, pending customary closing conditions and regulatory approvals. Once finalized, Solventum's Purification & Filtration business will be integrated into Thermo Fisher's Life Sciences Solutions segment.

Financially, the acquisition is projected to generate mid- to high-single digit organic growth for Thermo Fisher. Initially, the transaction will be dilutive to adjusted earnings per share (EPS) by $0.06 in the first year of ownership. However, excluding financing costs, it is expected to be accretive by $0.28 during the same period. This reflects the anticipated strong day-one cost synergies, given that Solventum’s allocated segment costs will be replaced by lower operational costs within Thermo Fisher.

Thermo Fisher anticipates realizing approximately $125 million in adjusted operating income from revenue and cost synergies by the fifth year following the close of the transaction. The expected long-term business growth and margin expansion opportunities make the financial returns on this acquisition compelling, with a projected double-digit internal rate of return.

The acquisition of Solventum’s Purification & Filtration business marks a bold step forward for Thermo Fisher Scientific, strengthening its portfolio in a vital segment of the life sciences market. With the promise of enhanced capabilities and significant financial returns, this strategic move underscores Thermo Fisher’s commitment to delivering value to its customers and shareholders. As the company prepares to integrate Solventum’s operations, industry watchers will be keen to see how this acquisition positions Thermo Fisher for future growth in the competitive landscape of scientific services.